The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature.
about
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.Characterization of hemopoietic engraftment kinetics and development of secondary cytopenia in AML post auto-SCT and its correlation with survival outcome.Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia.Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeLate relapses in acute myeloid leukemia: analysis of characteristics and outcomeShortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission.Gene expression profiles associated with pediatric relapsed AML.Biology and management of relapsed acute myeloid leukaemia.Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)Salvage therapy for relapsed or refractory acute myeloid leukemiaGuidelines on the management of acute myeloid leukaemia in adults.A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemiaPhase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensusVosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?Clofarabine combinations as acute myeloid leukemia salvage therapy.Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient.Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity.Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.Acute Myeloid Leukaemia: New Targets and Therapies.5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center.Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
P2860
Q33376920-E7A23AA3-117E-4298-BD13-9653416AFC2BQ33383210-AA763F43-169E-4035-BFD6-37BAF622C690Q33396282-7DCCE808-8428-44C1-B17B-483F9BFCA1B6Q33412354-CC6D8E7B-D627-4DFB-B0F8-643153BABC31Q33422405-0C68F5C7-AAE5-47ED-B76A-C273DE883C7BQ33734101-0BD44B11-7337-4B18-A014-7C99E37A10ADQ33737884-FF92F3DC-362A-4137-AD0A-93D7C496ABF8Q33769335-A029979A-D848-4703-BA19-403ECC78A3E0Q33861781-520CF917-037B-436E-813D-604D38BBEBFDQ34193514-2ABCCD03-7D53-42BE-85AE-F4B78EE6682DQ34255090-8975A7CE-690F-4DCF-AE46-65B1FE753AA0Q34316852-A25B6EAC-119A-45FF-9EF9-E7BC0DF5EA08Q35302035-84976601-1666-4FEB-9407-5C78E2A57B25Q36085026-48C70647-4058-41BF-8702-C8978AB4A06AQ36447920-B451BC5F-ECF4-4DEC-89A4-C0783BBCE287Q36612564-E2F5949B-6D85-4163-98A9-8A5FC3CF8E44Q36630107-7476CD48-8520-4128-90DE-65DD22BF4BEFQ36715960-0C411C5C-CD44-472E-8F03-9C5C96DB24C3Q37587057-B2B029B8-EC61-4E37-A355-95158A8F027FQ38042705-95F0517E-22F4-4245-8256-1DCDC2B901A9Q38106983-BA2EB574-9EB8-4A7E-B570-01AE90CFFBB5Q38469793-621176A8-DDCB-41C1-9C2C-C64C45105E7CQ38698037-960B2B7B-5ACE-499E-88E2-F751B6D67443Q39817951-6D66A09A-D163-4AF2-9F1D-494083589B54Q40055082-E46A6E5C-A393-4FA1-B61F-012C457B6110Q40554967-A8B9AD33-14EC-4098-9E9C-2D604A233477Q41478883-545A35ED-316C-44C2-BBB5-AFBF1DBDA3CDQ42048738-55E8C745-AD0C-4D7C-B29A-CCE1468A4FC6Q42941264-DD3D83D4-FFF8-47DA-9BD4-12D0D972A189Q43249320-1AE036E0-9B47-46D8-A322-AC33EDA4E447Q44086502-8B13ED5A-971D-40BE-9579-EB7BE09C32B7Q44115673-77BF98C6-9F8D-4892-849C-F25948F3DBEDQ46213367-68C626C2-458D-4FEE-9404-A16CBDB8222AQ46761676-2DA27806-1463-4734-9636-74302293F515Q46916537-E093F7E7-3F5B-4138-8E75-719A1508A6A5Q47347882-49A1CB2E-4BAB-4393-A4F0-E7C7E71A2657Q51039721-E791A11D-B982-48C3-896F-036EA71C8BAEQ52883093-72B470C9-CEE9-4CCB-A708-E413D61DD2A7Q53499124-97D25ABF-1DC0-4D4F-AAEF-326F211D52B7Q57073560-7C138ADA-C6AB-4E2F-85C3-564A085EF3D6
P2860
The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The treatment of acute myeloid ...... sive review of the literature.
@ast
The treatment of acute myeloid ...... sive review of the literature.
@en
type
label
The treatment of acute myeloid ...... sive review of the literature.
@ast
The treatment of acute myeloid ...... sive review of the literature.
@en
prefLabel
The treatment of acute myeloid ...... sive review of the literature.
@ast
The treatment of acute myeloid ...... sive review of the literature.
@en
P2860
P1433
P1476
The treatment of acute myeloid ...... sive review of the literature.
@en
P2093
Lance H Leopold
Roel Willemze
P2860
P304
P356
10.1080/1042819021000006529
P577
2002-09-01T00:00:00Z